Stocksigma LogoStocksigma Logo

Strides Pharma Reports Robust Q2FY27 Results Led by Ex-US Growth

Strides Pharma Science posted a 17.1% YoY revenue growth to ₹14,297m for Q2FY27 ended 30th Sep'26, driven by Ex-US markets surging 31.0% YoY to ₹6,963m and

Strides Pharma Reports Robust Q2FY27 Results Led by Ex-US Growth

Strides Pharma Science Ltd · Press Release · 30 Oct 2026, 12:24 am

Strides Pharma Reports Robust Q2FY27 Results Led by Ex-US Growth Strides Pharma Science posted a 17.1% YoY revenue growth to ₹14,297m for Q2FY27 ended 30th Sep'26, driven by Ex-US markets surging 31.0% YoY to ₹6,963m and surpassing US revenue of ₹6,855m (up 9.0% YoY). EBITDA rose 8.4% YoY to a record ₹2,509m, despite margins contracting 140 bps YoY to 17.6% due to freight and raw material pressures. Operational PAT increased 11.5% YoY to ₹1,358m, while reported PAT reached ₹1,341m. H1 net debt rose ₹2,114m amid higher inventory holding.

Original exchange filing (PDF)

More announcements from Strides Pharma Science Ltd

All Strides Pharma Science Ltd announcements